GSK plc (GSK, GSK.L) has announced longer-term results from the Phase II collaborative study, conducted with Memorial Sloan Kettering Cancer Center, evaluating the efficacy of Jemperli (dostarlimab) as a first-line treatment alternative to surgery for mismatch repair-deficient, locally advanced rectal cancer. The trial demonstrated a 100% clinical complete response rate in all 42 patients who completed dostarlimab treatment.
Hesham Abdullah, Senior Vice President and Global Head of Oncology R&D at GSK, commented: "We are eager to continue our evaluation of dostarlimab in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies."
For more health news, visit rttnews.com.
